Sign In
Buy CCXI
$10.24
+0.0150 (+0.147%)
At Close: Jun 03, 2026
ChemoCentryx Stock Plunges As FDA Briefing Document Casts Doubt On Vasculitis Candidate Avacopan's Data
01:19pm, Tuesday, 04'th May 2021
ChemoCentryx Inc (NASDAQ: CCXI) shares plunged after an FDA briefing document indicates the agency has “several areas of concerns” with its vasculitis candidate, avacopan. The FDA document rai
CCXI Stock: From $48.82 To $24.60 (49.61% Decrease) Intraday Explanation
12:31pm, Tuesday, 04'th May 2021
The stock price of ChemoCentryx Inc (NASDAQ: CCXI) fell from $48.82 to $24.60 (down 49.61%) during intraday trading. This is why it happened.
ChemoCentryx's stock dives after critique from the FDA about experimental treatment for rare autoimmune disease
12:03pm, Tuesday, 04'th May 2021
Shares of ChemoCentryx Inc. plunged 44.8% in trading on Tuesday after the Food and Drug Administration questioned the rationale behind some of the clinical data for avacopan, an experimental treatment
ChemoCentryx, Inc.'s (CCXI) CEO Dr. Thomas Schall on Q1 2021 Results - Earnings Call Transcript
11:52pm, Thursday, 29'th Apr 2021
ChemoCentryx, Inc.'s (CCXI) CEO Dr. Thomas Schall on Q1 2021 Results - Earnings Call Transcript
ChemoCentryx (CCXI) Reports Q1 Loss, Tops Revenue Estimates
06:47pm, Thursday, 29'th Apr 2021
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -7.50% and 19.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
04:05pm, Thursday, 29'th Apr 2021
-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee schedule
-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the first h
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
08:30am, Wednesday, 07'th Apr 2021
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. E
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
08:30am, Monday, 08'th Mar 2021
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company's Executive Vice President and Chief Finan
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2020 Results - Earnings Call Transcript
12:19am, Tuesday, 02'nd Mar 2021
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2020 Results - Earnings Call Transcript
ChemoCentryx (CCXI) Reports Q4 Loss, Misses Revenue Estimates
06:57pm, Monday, 01'st Mar 2021
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -34.38% and -51.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
04:05pm, Monday, 01'st Mar 2021
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associate
ChemoCentryx to Present at Two Upcoming Investor Conferences
08:30am, Thursday, 25'th Feb 2021
MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two up
ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
08:30am, Tuesday, 23'rd Feb 2021
MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released aft
-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan's eff
